REATA PHARMACEUTICALS INC Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2015 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Reata Pharmaceuticals Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2015 to Q2 2023.
  • Reata Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $20.4M, a 46.9% increase year-over-year.
  • Reata Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2023 was $87.8M, a 51% increase year-over-year.
  • Reata Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2022 was $58.7M, a 3.39% increase from 2021.
  • Reata Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2021 was $56.8M, a 1.44% decline from 2020.
  • Reata Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2020 was $57.6M, a 118% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $87.8M $20.4M +$6.5M +46.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $81.3M $38.1M +$22.6M +146% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-10
Q4 2022 $58.7M $15M -$249K -1.64% Oct 1, 2022 Dec 31, 2022 10-K 2023-02-24
Q3 2022 $59M $14.4M +$789K +5.78% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $58.2M $13.9M +$620K +4.68% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $57.6M $15.4M +$765K +5.21% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $56.8M $15.2M +$3.28M +27.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-24
Q3 2021 $53.5M $13.7M +$2.08M +17.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $51.5M $13.2M -$1.55M -10.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $53M $14.7M -$4.63M -24% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $57.6M $12M -$341K -2.77% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-24
Q3 2020 $58M $11.6M +$6.2M +115% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $51.8M $14.8M +$10.3M +230% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $41.5M $19.3M +$15.1M +357% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $26.4M $12.3M +$9.52M +344% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $16.9M $5.38M +$2.64M +96% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $14.2M $4.48M +$1.93M +75.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $12.3M $4.23M +$1.74M +70.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $10.6M $2.77M +$968K +53.8% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 $9.58M $2.75M +$1.2M +77.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $8.38M $2.55M +$970K +61.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $7.41M $2.49M +$882K +55% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $6.53M $1.8M +$884K +96.5% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-19
Q3 2017 $5.65M $1.55M +$829K +116% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $4.82M $1.58M +$1.14M +255% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 $3.68M $1.6M +$1.31M +455% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $2.37M $916K Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 $716K +$390K +120% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 $446K +$98K +28.2% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 $289K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 $326K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 $348K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.